Stockreport

Delcath's Hepzato Kit offers better disease control than immunotherapy [Yahoo! Finance]

Delcath Systems, Inc.  (DCTH) 
US:NASDAQ Investor Relations: delcath.com/investors
PDF superior liver disease control and progression-free survival (PFS) in patients with metastatic uveal melanoma with liver metastases. The kit combines the chemotherapy [Read more]